CG Oncology is a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer, with a primary focus on bladder cancer. Its lead programs aim to treat patients whose disease has not responded adequately to standard therapies such as BCG. The company targets urologic oncology specialists and clinical trial networks rather than commercial mass markets at this stage. A bladder-cancer-focused pipeline of virus-based immunotherapy is its main distinguishing feature.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -41.4 | — |
| Q3 2025 | 1.7 | — | -43.8 | — |
| Q4 2025 | 2.3 | — | -41.3 | — |
| Q1 2026 | 1.1 | — | -60.2 | — |
| Q2 2026 | 1.2 | — | -79.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Rush Enterprises, Inc. (RUSHA), GRAIL, Inc. (GRAL), Waystar Holding Corp. (WAY), PriceSmart, Inc. (PSMT), Mirum Pharmaceuticals, Inc. (MIRM), Grifols, S.A. (GRFS)